Nuzenio

Immunopharma

Immunopharma news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 14 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.stsimplywall.st · Sat, 08 Aug 2026 13:28:42 GMTEstrella Immunopharma Inc (ESLA) Stock News Today - TradingKeyTradingKey · Sat, 08 Aug 2026 12:31:44 GMTLyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMTLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:37 GMTThis Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - BenzingaBenzinga · Thu, 06 Aug 2026 14:12:18 GMTLyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeatMarketBeat · Thu, 06 Aug 2026 13:40:43 GMTLYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - BitgetBitget · Thu, 06 Aug 2026 03:27:05 GMTStifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.comInvesting.com · Wed, 05 Aug 2026 21:33:52 GMT

Timeline

Sat, 08 Aug 2026 13:28:42 GMTPossible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st
Sat, 08 Aug 2026 12:31:44 GMTEstrella Immunopharma Inc (ESLA) Stock News Today - TradingKey
Thu, 06 Aug 2026 20:35:29 GMTLyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView
Thu, 06 Aug 2026 20:14:37 GMTLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - The Manila Times
Thu, 06 Aug 2026 14:12:18 GMTThis Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Thu, 06 Aug 2026 13:40:43 GMTLyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Immunopharma.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.